DEPLOYDatabase

Company

Synchron

Synchron is a brain-computer interface (BCI) company developing the Stentrode, a stentrode-based BCI implant that does not require open-brain surgery.

Founded
2016
HQ
New York, NY, USA

Funding

$200.0M

Models

1

Overview

Synchron is a brain-computer interface (BCI) company developing the Stentrode, a stentrode-based BCI implant that does not require open-brain surgery. Founded by neurologist Tom Oxley, the company has raised over $345M in total funding including a $200M Series D in 2024. Synchron's COMMAND and SWITCH clinical trials demonstrated no serious device-related adverse events across 6 patients, and the FDA has approved the Stentrode for early feasibility studies. The company is based in New York with origins in Melbourne, Australia.

Verified record

Verified deployments
None on file
Active incidents
None on file

DEPLOY Intelligence

Market intelligence for physical AI

Analyst-grade signals, competitive tracking, and investment context across the global physical AI landscape. Launching 2026.

Key facts

CEO

Tom Oxley (Founder, neurologist, Mount Sinai)

Total funding

over $345M ($200M Series D 2024, $75M Series C 2022)

Product

Stentrode (endovascular BCI implant, no open-brain surgery)

Clinical trials

COMMAND (US, FDA-approved), SWITCH (Australia, 4 patients)

Safety

No serious device-related adverse events in 6 patients

Target

Patients with severe paralysis (ALS) to communicate via thought

Data & sources

Web sources

1

1 source backing this record.View all →

Current leadership (1)

  • Tom Oxley Founder & CEOreported, not verified

Founders (1)

Safety record

No incidents on record for Synchron.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Recent coverage

Synchron in third-party press

Peer companies